ImmunoACT

Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia. It offers other pipeline products which include Actalycabtagene autoleucel​ for B-lymphoid malignancies​, HCAR2 for multiple myeloma, and HCAr3 for Glioblastoma multiforme, and neuroblastoma​.